In reply: What is adequate hypertension control?

Article Type
Changed
Tue, 04/17/2018 - 10:40
Display Headline
In reply: What is adequate hypertension control?

In Reply: First, I am gratified by the tremendous interest in the care of the hypertensive patient that my article has generated. Dr. Norenberg and Dr. Kelleher are insightful clinicians, as evidenced by the issues that their letters raise. Secondly, as I am now 54 years old, SHEP’s definition of “elderly” as 60 years old and older appears less accurate to me! However, I think we might all agree that to date there has not been a trial with people 65 years old and younger that has not shown benefit to treatment of the blood pressure to less than 140/90 mm Hg.

I believe that Dr. Kelleher’s quest for more “evidence-based” data refers to treatment data in patients above that age. Hopefully, this quest will be answered by the results of the Hypertension in the Very Elderly Trial (HYVET).1 In this trial, 3,845 patients older than 80 years were treated to less than 140/90 mm Hg. On July 12, 2007, the trial was stopped by the data safety and monitoring board, with the expectation of published results at the European Society of Hypertension and International Society of Hypertension joint meeting in Berlin in 2008.

Third, I must remind the reader that in practicing evidence-based medicine, we clinicians always must interpret the results of double-blind placebo-controlled trials, which tell us the mean effect of a treatment, but apply this information to the individual patient seated in front of us. A recent study2 of individual blood pressure response to four forms of monotherapy showed that, in some patients, the blood pressure rose with hydrochlorothiazide instead of falling!

Fourth, Dr. Kelleher implies, correctly, that not all patients can reach the target of less than 140/90. In this regard I think the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)3 is very instructive. ALLHAT is the first trial ever to show improvement in the percent of people reaching goal blood pressure, rising from 52% to 63% during the 5-year study. ALLHAT shows us how good we can be and that we should not accept the failure to reach goal blood pressure in at least two-thirds of our patients.

The final and most important point is that the time for arguing the guideline recommendations4–6 based on our own opinion is past. Third-party payers and patients are demanding we meet those guidelines until new information suggests that they need to be altered. HYVET may force such an alteration, but until then Dr. Norenberg, Dr. Kelleher, and I must attempt to reach the target of less than 140/90 in the majority of our patients.

The final and most important point is that the time for arguing the guideline recommendations4–6 based on our own opinion is past. Third-party payers and patients are demanding we meet those guidelines until new information suggests that they need to be altered. HYVET may force such an alteration, but until then Dr. Norenberg, Dr. Kelleher, and I must attempt to reach the target of less than 140/90 in the majority of our patients.

References
  1. Imperial College London. Trial stops after stroke and mortality significantly reduced by blood pressure-lowering treatment for those aged 80 and over (Press Release). Accessed December 31, 2007. www.servier.com/pro/identification.asp.
  2. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007; 20:311–318.
  3. ALLHAT Collaborative Research Group. Major cardiovascular Events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967–1975. Correction in JAMA 2000; 288:2976.
  4. Khan NA, McAlister FA, Rabkin SW, et al Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II—therapy. Can J Cardiol 2006; 22:583–593.
  5. Chobanian AV, Bakris GL, Black HR, et al National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560–2572.
  6. Mancia G, De Backer G, Dominiczak A, et al the Task Force For the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105–1187.
Article PDF
Author and Disclosure Information

John W. Graves, MD
Mayo Clinic, Rochester, MN

Issue
Cleveland Clinic Journal of Medicine - 75(3)
Publications
Topics
Page Number
168, 170
Sections
Author and Disclosure Information

John W. Graves, MD
Mayo Clinic, Rochester, MN

Author and Disclosure Information

John W. Graves, MD
Mayo Clinic, Rochester, MN

Article PDF
Article PDF
Related Articles

In Reply: First, I am gratified by the tremendous interest in the care of the hypertensive patient that my article has generated. Dr. Norenberg and Dr. Kelleher are insightful clinicians, as evidenced by the issues that their letters raise. Secondly, as I am now 54 years old, SHEP’s definition of “elderly” as 60 years old and older appears less accurate to me! However, I think we might all agree that to date there has not been a trial with people 65 years old and younger that has not shown benefit to treatment of the blood pressure to less than 140/90 mm Hg.

I believe that Dr. Kelleher’s quest for more “evidence-based” data refers to treatment data in patients above that age. Hopefully, this quest will be answered by the results of the Hypertension in the Very Elderly Trial (HYVET).1 In this trial, 3,845 patients older than 80 years were treated to less than 140/90 mm Hg. On July 12, 2007, the trial was stopped by the data safety and monitoring board, with the expectation of published results at the European Society of Hypertension and International Society of Hypertension joint meeting in Berlin in 2008.

Third, I must remind the reader that in practicing evidence-based medicine, we clinicians always must interpret the results of double-blind placebo-controlled trials, which tell us the mean effect of a treatment, but apply this information to the individual patient seated in front of us. A recent study2 of individual blood pressure response to four forms of monotherapy showed that, in some patients, the blood pressure rose with hydrochlorothiazide instead of falling!

Fourth, Dr. Kelleher implies, correctly, that not all patients can reach the target of less than 140/90. In this regard I think the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)3 is very instructive. ALLHAT is the first trial ever to show improvement in the percent of people reaching goal blood pressure, rising from 52% to 63% during the 5-year study. ALLHAT shows us how good we can be and that we should not accept the failure to reach goal blood pressure in at least two-thirds of our patients.

The final and most important point is that the time for arguing the guideline recommendations4–6 based on our own opinion is past. Third-party payers and patients are demanding we meet those guidelines until new information suggests that they need to be altered. HYVET may force such an alteration, but until then Dr. Norenberg, Dr. Kelleher, and I must attempt to reach the target of less than 140/90 in the majority of our patients.

The final and most important point is that the time for arguing the guideline recommendations4–6 based on our own opinion is past. Third-party payers and patients are demanding we meet those guidelines until new information suggests that they need to be altered. HYVET may force such an alteration, but until then Dr. Norenberg, Dr. Kelleher, and I must attempt to reach the target of less than 140/90 in the majority of our patients.

In Reply: First, I am gratified by the tremendous interest in the care of the hypertensive patient that my article has generated. Dr. Norenberg and Dr. Kelleher are insightful clinicians, as evidenced by the issues that their letters raise. Secondly, as I am now 54 years old, SHEP’s definition of “elderly” as 60 years old and older appears less accurate to me! However, I think we might all agree that to date there has not been a trial with people 65 years old and younger that has not shown benefit to treatment of the blood pressure to less than 140/90 mm Hg.

I believe that Dr. Kelleher’s quest for more “evidence-based” data refers to treatment data in patients above that age. Hopefully, this quest will be answered by the results of the Hypertension in the Very Elderly Trial (HYVET).1 In this trial, 3,845 patients older than 80 years were treated to less than 140/90 mm Hg. On July 12, 2007, the trial was stopped by the data safety and monitoring board, with the expectation of published results at the European Society of Hypertension and International Society of Hypertension joint meeting in Berlin in 2008.

Third, I must remind the reader that in practicing evidence-based medicine, we clinicians always must interpret the results of double-blind placebo-controlled trials, which tell us the mean effect of a treatment, but apply this information to the individual patient seated in front of us. A recent study2 of individual blood pressure response to four forms of monotherapy showed that, in some patients, the blood pressure rose with hydrochlorothiazide instead of falling!

Fourth, Dr. Kelleher implies, correctly, that not all patients can reach the target of less than 140/90. In this regard I think the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)3 is very instructive. ALLHAT is the first trial ever to show improvement in the percent of people reaching goal blood pressure, rising from 52% to 63% during the 5-year study. ALLHAT shows us how good we can be and that we should not accept the failure to reach goal blood pressure in at least two-thirds of our patients.

The final and most important point is that the time for arguing the guideline recommendations4–6 based on our own opinion is past. Third-party payers and patients are demanding we meet those guidelines until new information suggests that they need to be altered. HYVET may force such an alteration, but until then Dr. Norenberg, Dr. Kelleher, and I must attempt to reach the target of less than 140/90 in the majority of our patients.

The final and most important point is that the time for arguing the guideline recommendations4–6 based on our own opinion is past. Third-party payers and patients are demanding we meet those guidelines until new information suggests that they need to be altered. HYVET may force such an alteration, but until then Dr. Norenberg, Dr. Kelleher, and I must attempt to reach the target of less than 140/90 in the majority of our patients.

References
  1. Imperial College London. Trial stops after stroke and mortality significantly reduced by blood pressure-lowering treatment for those aged 80 and over (Press Release). Accessed December 31, 2007. www.servier.com/pro/identification.asp.
  2. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007; 20:311–318.
  3. ALLHAT Collaborative Research Group. Major cardiovascular Events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967–1975. Correction in JAMA 2000; 288:2976.
  4. Khan NA, McAlister FA, Rabkin SW, et al Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II—therapy. Can J Cardiol 2006; 22:583–593.
  5. Chobanian AV, Bakris GL, Black HR, et al National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560–2572.
  6. Mancia G, De Backer G, Dominiczak A, et al the Task Force For the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105–1187.
References
  1. Imperial College London. Trial stops after stroke and mortality significantly reduced by blood pressure-lowering treatment for those aged 80 and over (Press Release). Accessed December 31, 2007. www.servier.com/pro/identification.asp.
  2. Hiltunen TP, Suonsyrja T, Hannila-Handelberg T, et al. Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study). Am J Hypertens 2007; 20:311–318.
  3. ALLHAT Collaborative Research Group. Major cardiovascular Events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283:1967–1975. Correction in JAMA 2000; 288:2976.
  4. Khan NA, McAlister FA, Rabkin SW, et al Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: part II—therapy. Can J Cardiol 2006; 22:583–593.
  5. Chobanian AV, Bakris GL, Black HR, et al National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560–2572.
  6. Mancia G, De Backer G, Dominiczak A, et al the Task Force For the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007; 25:1105–1187.
Issue
Cleveland Clinic Journal of Medicine - 75(3)
Issue
Cleveland Clinic Journal of Medicine - 75(3)
Page Number
168, 170
Page Number
168, 170
Publications
Publications
Topics
Article Type
Display Headline
In reply: What is adequate hypertension control?
Display Headline
In reply: What is adequate hypertension control?
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

In reply: What is adequate hypertension control?

Article Type
Changed
Fri, 07/20/2018 - 07:00
Display Headline
In reply: What is adequate hypertension control?
Article PDF
Author and Disclosure Information

John W. Graves, MD
Mayo Clinic, Rochester, MN

Issue
Cleveland Clinic Journal of Medicine - 74(12)
Publications
Topics
Page Number
848-849
Sections
Author and Disclosure Information

John W. Graves, MD
Mayo Clinic, Rochester, MN

Author and Disclosure Information

John W. Graves, MD
Mayo Clinic, Rochester, MN

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 74(12)
Issue
Cleveland Clinic Journal of Medicine - 74(12)
Page Number
848-849
Page Number
848-849
Publications
Publications
Topics
Article Type
Display Headline
In reply: What is adequate hypertension control?
Display Headline
In reply: What is adequate hypertension control?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

What is adequate hypertension control? Having your dinner and dessert too

Article Type
Changed
Thu, 07/19/2018 - 11:24
Display Headline
What is adequate hypertension control? Having your dinner and dessert too
Article PDF
Author and Disclosure Information

John W. Graves, MD
Associate Professor of Medicine; Consultant, Division of Nephrology and Hypertension; Mayo Clinic College of Medicine

Address: John Graves, MD, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905; e-mail: Graves.John@mayo.edu

The author has indicated that he has served as a consultant for King Pharmaceuticals.

Issue
Cleveland Clinic Journal of Medicine - 74(10)
Publications
Topics
Page Number
748-754
Sections
Author and Disclosure Information

John W. Graves, MD
Associate Professor of Medicine; Consultant, Division of Nephrology and Hypertension; Mayo Clinic College of Medicine

Address: John Graves, MD, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905; e-mail: Graves.John@mayo.edu

The author has indicated that he has served as a consultant for King Pharmaceuticals.

Author and Disclosure Information

John W. Graves, MD
Associate Professor of Medicine; Consultant, Division of Nephrology and Hypertension; Mayo Clinic College of Medicine

Address: John Graves, MD, Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905; e-mail: Graves.John@mayo.edu

The author has indicated that he has served as a consultant for King Pharmaceuticals.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 74(10)
Issue
Cleveland Clinic Journal of Medicine - 74(10)
Page Number
748-754
Page Number
748-754
Publications
Publications
Topics
Article Type
Display Headline
What is adequate hypertension control? Having your dinner and dessert too
Display Headline
What is adequate hypertension control? Having your dinner and dessert too
Sections
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media